All In Biotech

Drug Trial Radar · NCT00488631

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Apr 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,228

Actual

Start

Sep 2007

Primary completion

Oct 2011

Study completion Feb 2015

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 20, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.

Conditions

  • Colitis, Ulcerative

Interventions

  • PlaceboBiological

    Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

  • Golimumab 50 mgBiological

    Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

  • Golimumab 100 mgBiological

    Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

  • Golimumab 200 mgBiological

    Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in Clinical Response Through Week 54Time frame: Induction Baseline, Week 0 through Week 54

Locations

297 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Merced, California

  • Site not named

    Orange, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    Lakewood, Colorado

  • Site not named

    Littleton, Colorado

  • Site not named

    Bristol, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Boca Raton, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Naples, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Snellville, Georgia

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Clive, Iowa

  • Site not named

    Fort Dodge, Iowa

  • Site not named

    Pratt, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Monroe, Louisiana

  • Site not named

    Hagerstown, Maryland

  • Site not named

    Hollywood, Maryland

  • Site not named

    Laurel, Maryland

  • Site not named

    Worcester, Massachusetts

Showing 40 of 297 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.